Phathom Pharmaceuticals, Inc.
NNASDAQ:PHATCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven L. Basta
- Full Time Employees
- 371
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 100 Campus Drive Florham Park NJ United States 07932
- IPO Date
- Oct 25, 2019
- CIK
- 0001783183
- Website
- phathompharma.com
- Similar Companies
- Business
- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company offers VOQUEZNA (vonoprazan), a potassium-competitive acid blocker (PCAB) approved for healing all grades of erosive esophagitis (EE), relieving heartburn in non-erosive gastroesophageal reflux disease (GERD), and as an H. pylori eradication regimen in combination with amoxicillin and clarithromycin or amoxicillin alone; VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which are co-packaged therapies for H. pylori infection; and VOQUEZNA TRIPLE 10 PAK, a new regimen launched to improve patient compliance through smaller pill sizes. Phathom operates primarily in the United States, with headquarters in Florham Park, New Jersey, and was founded in 2019 following the acquisition of assets from Takeda Pharmaceuticals. In recent developments, the company expanded its VOQUEZNA portfolio with the FDA approval and launch of VOQUEZNA TRIPLE 10 PAK in late 2024, enhancing treatment accessibility for H. pylori; entered a strategic collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in 2025 to investigate vonoprazan's potential in pulmonary arterial hypertension; and reported positive Phase 3 topline results for vonoprazan in eosinophilic esophagitis (EoE) in mid-2025, positioning it as a potential first PCAB therapy in this indication. Phathom targets gastroenterologists, primary care physicians, and patients with acid-related disorders, operating within the specialty pharmaceuticals segment of the biopharma industry.
Company News
Implied Volatility Surging for Phathom Pharmaceuticals Stock Options
Phathom Pharmaceuticals to Participate in November Investor Conferences
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals Provides Update on FDA Litigation
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript